论文部分内容阅读
作为病原体,人类诺瓦克病毒(NOV)占全球非细菌性胃肠炎的95%。目前,没有可用于对抗人类NOV病毒的疫苗,因为它不可培养,而且缺乏小动物模型。最近研究表明,表达人类No V衣壳蛋白(r VSV-VP1)的重组水泡性口炎病毒(r VSV)在小鼠体内引起强烈的免疫应答。为了进一步改善候选疫苗的安全性和有效性,热休克蛋白70(HSP70)被插入到r VSV-VP1骨架载体。作为双重插入,萤火虫
As a pathogen, human Norovirus (NOV) accounts for 95% of global non-bacterial gastroenteritis. Currently, there is no vaccine that can be used against the human NOV virus because it is not culturable and lacks a small animal model. Recent studies have shown that recombinant vesicular stomatitis virus (r VSV) expressing human NoV capsid protein (rVSV-VP1) elicits a strong immune response in mice. To further improve the safety and efficacy of the candidate vaccine, heat shock protein 70 (HSP70) was inserted into the rVSV-VP1 backbone vector. As double insertion, firefly